Table 2. Univariable Association with MACE and Mortality of Patients in the STUDY Group.
| MACE | All-cause Mortality | |||||||
|---|---|---|---|---|---|---|---|---|
| HR | HR 95% CI | P value | HR | HR 95% CI | P value | |||
| Patient Age (years) | 1.00 | 0.98 | 1.03 | 0.81 | 1.05 | 1.00 | 1.09 | 0.04 |
| Female Gender | 0.84 | 0.42 | 1.67 | 0.61 | 1.08 | 0.40 | 2.95 | 0.88 |
| Body Mass Index > 30 kg/m2 | 0.66 | 0.34 | 1.27 | 0.22 | 0.44 | 0.16 | 1.19 | 0.11 |
| Years of Diabetes Diagnosis | 0.98 | 0.94 | 1.02 | 0.39 | 0.99 | 0.93 | 1.05 | 0.70 |
| Hemoglobin A1c (%) | 0.87 | 0.67 | 1.12 | 0.27 | 0.91 | 0.62 | 1.33 | 0.61 |
| Resting Heart Rate > 100 beats/min | 0.95 | 0.29 | 3.12 | 0.93 | 0.75 | 0.10 | 5.71 | 0.78 |
| Hx. of PCI | 2.41 | 1.00 | 5.81 | 0.05 | 2.00 | 0.58 | 6.94 | 0.28 |
| Hx. of CABG | 1.43 | 0.56 | 3.71 | 0.46 | 0.46 | 0.06 | 3.49 | 0.45 |
| Hx. of Hypertension | 0.65 | 0.32 | 1.29 | 0.22 | 0.61 | 0.23 | 1.66 | 0.34 |
| Hx. of Hypercholesterolemia | 0.63 | 0.33 | 1.23 | 0.18 | 0.48 | 0.19 | 1.23 | 0.13 |
| Total Cholesterol Value (mg/dL) | 1.00 | 0.99 | 1.00 | 0.32 | 0.99 | 0.97 | 1.00 | 0.06 |
| HDL Cholesterol (mg/dL) | 1.00 | 0.97 | 1.03 | 0.81 | 1.01 | 0.97 | 1.05 | 0.62 |
| Total/HDL Cholesterol Ratio | 0.83 | 0.55 | 1.23 | 0.34 | 0.42 | 0.22 | 0.81 | 0.009 |
| Heavy Tobacco Use | 1.16 | 0.58 | 2.33 | 0.67 | 1.94 | 0.75 | 5.03 | 0.17 |
| Family Hx. of CAD | 0.57 | 0.18 | 1.87 | 0.35 | 0.82 | 0.19 | 3.59 | 0.79 |
| Systolic Blood Pressure at Rest (mmHg) | 1.00 | 0.98 | 1.01 | 0.55 | 1.00 | 0.98 | 1.02 | 0.80 |
| UKPDS 5-year Probability of MACE | 0.22 | 0.01 | 15.53 | 0.49 | 7.38 | 0.06 | 986.72 | 0.42 |
| Beta-blocker | 0.89 | 0.47 | 1.71 | 0.74 | 0.87 | 0.34 | 2.20 | 0.76 |
| Calcium Blocker | 1.18 | 0.58 | 2.39 | 0.64 | 0.84 | 0.27 | 2.54 | 0.75 |
| Angiotensin-converting enzyme inhibitor | 0.75 | 0.40 | 1.42 | 0.37 | 0.71 | 0.28 | 1.81 | 0.50 |
| Cholesterol Lowering Medication | 0.80 | 0.41 | 1.54 | 0.50 | 0.37 | 0.15 | 0.95 | 0.04 |
| Aspirin | 1.20 | 0.63 | 2.31 | 0.57 | 1.22 | 0.47 | 3.16 | 0.68 |
| Non-sinus rhythm | 1.71 | 0.60 | 4.91 | 0.32 | 1.62 | 0.37 | 7.11 | 0.99 |
| LVH on ECG | 1.13 | 0.27 | 4.70 | 0.87 | -- | -- | -- | -- |
| Left bundle branch block | 1.77 | 0.62 | 5.05 | 0.28 | 2.31 | 0.66 | 8.04 | 0.19 |
| Right bundle branch block | -- | -- | -- | -- | -- | -- | -- | -- |
| QRS duration (ms) | 1.00 | 0.98 | 1.02 | 0.90 | 1.01 | 0.98 | 1.03 | 0.65 |
| Corrected QT interval† (ms) | 0.99 | 0.98 | 1.00 | 0.24 | 0.99 | 0.97 | 1.01 | 0.22 |
| ST depression ≥ 1 mm | 1.99 | 0.82 | 4.84 | 0.13 | 1.72 | 0.49 | 5.98 | 0.40 |
| T inversion in > 2 contiguous leads | 1.80 | 0.89 | 3.64 | 0.10 | 2.10 | 0.81 | 5.44 | 0.12 |
| LV Mass (grams) | 1.01 | 1.00 | 1.01 | 0.09 | 0.99 | 0.98 | 1.00 | 0.23 |
| LVEDD (per mm) | 1.00 | 0.95 | 1.05 | 0.91 | 0.97 | 0.91 | 1.04 | 0.38 |
| LVEDV index (per 10 ml/m2) | 1.19 | 1.05 | 1.34 | 0.006 | 1.02 | 0.86 | 1.21 | 0.79 |
| LVESV index (per 10 ml/m2) | 1.18 | 1.07 | 1.31 | <0.001 | 1.04 | 0.89 | 1.21 | 0.63 |
| LVEF (per 10%) | 0.79 | 0.65 | 0.96 | 0.02 | 0.96 | 0.72 | 1.30 | 0.81 |
| Resting Wall Motion Abnormality | 1.91 | 0.99 | 3.67 | 0.05 | 1.90 | 0.75 | 4.83 | 0.18 |
| Presence of LGE | 3.71 | 1.93 | 7.12 | <0.001 | 3.61 | 1.42 | 9.19 | 0.007 |
| LGE (% of LV Mass, per 10%) | 1.63 | 1.12 | 2.38 | 0.01 | 1.60 | 0.87 | 2.92 | 0.13 |
| TEMean | 2.04 | 0.72 | 5.75 | 0.18 | 3.97 | 1.09 | 14.48 | 0.04 |
| TEMax | 1.26 | 0.99 | 1.61 | 0.06 | 1.32 | 0.96 | 1.82 | 0.09 |
| TEMax (LAD territory) | 0.98 | 0.61 | 1.56 | 0.92 | 1.22 | 0.76 | 1.96 | 0.42 |
| TEMax (RCA territory) | 1.51 | 1.15 | 1.98 | 0.003 | 1.51 | 1.08 | 2.12 | 0.02 |
| TEMax (LCx territory) | 1.08 | 0.47 | 2.47 | 0.85 | 1.47 | 0.44 | 4.84 | 0.53 |
| No. of Seg with LGE | 1.14 | 0.96 | 1.36 | 0.14 | 1.26 | 1.02 | 1.56 | 0.03 |
| No. of Seg with LGE (LAD) | 1.11 | 0.62 | 2.00 | 0.73 | 1.61 | 0.86 | 2.99 | 0.14 |
| No. of Seg with LGE (RCA) | 1.59 | 1.11 | 2.29 | 0.01 | 1.50 | 1.03 | 2.17 | 0.03 |
| No. of Seg with LGE (LCx) | 1.25 | 0.65 | 2.41 | 0.50 | 1.67 | 0.77 | 3.64 | 0.20 |
PCI=Percutaneous Coronary Intervention; CABG=Coronary Artery Bypass Grafting; ACE=Angiotensin Converting Enzyme; LVH=Left Ventricular Hypertrophy; TE=Transmural Extent of Late Gadolinium Enhancement; LAD=Left Anterior Descending Artery; RCA=Right Coronary Artery; LCx=Left Circumflex Artery; -- events too low for HR estimation.